Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27288353 | 0.89 | ALDH1A1 (0.39) | ALDH1A1LMNAKDM4ESLC22A2SLC22A1 | |
| SCHEMBL246748 | 0.88 | GRIN2D (0.33) | ALDH1A1LMNAKDM4EACKR3ACHE | |
| Iodide SCHEMBL4001778 | 0.84 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9AGAAPAOX | |
| SCHEMBL2906622 | 0.81 | ALDH1A1 (0.45) | ALDH1A1NPC1RAB9AGAAPAOX | |
| SCHEMBL11981678 | 0.81 | ALDH1A1 (0.43) | ALDH1A1NPC1RAB9AGAAPAOX | |
| Buformin SCHEMBL27451 | 0.79 | GRIN2D (0.44) | ACHE | |
| SCHEMBL3070655 | 0.78 | MEN1 (0.43) | ALOX15 | |
| Buformin SCHEMBL3644254 | 0.77 | GRIN2D (0.42) | ACHE | |
| SCHEMBL786167 | 0.77 | SPHK1 (0.44) | ALDH1A1TSHR | |
| Buformin SCHEMBL6018 | 0.77 | GRIN2D (0.42) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012036392-A3 | HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING THE SAME | 주식회사 아이지세라피 (KR) | 2012-05-10 | — | — | WO | claimed |
| EP-1930376-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2011-12-07 | — | — | EP | claimed |
| EP-4692247-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022211-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-01-22 | — | — | US | disclosed |
| EP-4656672-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4180482-B1 | MOISTURE-CURABLE COMPOSITION | NITTO KASEI CO LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4174053-B1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4569023-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025111365-A1 | METHOD OF PREPARING A MOISTURE CURABLE RESIN COMPOSITION WITH A NON-TIN CATALYST | KANEKA AMERICAS HOLDING, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4105262-B1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORP (JP) | 2025-04-02 | — | — | EP | disclosed |
| US-20090182099-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182091-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090171025-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1992665-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1990370-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1988127-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1985666-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1939257-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1930376-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | KDM2B, SETDB1, ASH2L | ALDH1A1 615/4885NPC1 4130/4885RAB9A 2668/4885 |
| US-20260022211-A1 | CURABLE COMPOSITION | H1-4, H1-0, H1-2 | ALDH1A1 2939/4885NPC1 4047/4885RAB9A 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.